Cancer Vaccines

Latest Headlines

Latest Headlines

Looking to Opdivo combo trial, Heat ends cancer vaccine PhII

Cancer vaccine/checkpoint inhibitor partnerships just keep rolling in. On Tuesday, oncology company Heat Biologics announced that it's the most recent to get involved, though it'll be applying the method to a cancer that so far others haven't.

AZ's MedImmune offers up $727M to get its hands on Inovio cancer vaccine

MedImmune on Monday announced a development deal worth up to $727 million--$27 million upfront--to acquire exclusive rights to Inovio Pharmaceuticals' HPV cancer vaccine INO-3112 and to develop additional cancer vaccine candidates.

Cancer vaccines field to see sizable growth, report says

Though cancer vaccines have seen limited success and late-stage clinical failures in recent years, a new report by Infiniti Research suggests they're here to stay and will begin taking off in a big way.

Merck, Amgen to test Keytruda/T-Vec combo in head and neck cancer

While the FDA deliberates whether to approve Amgen's melanoma-fighting vaccine, T-Vec, as a monotherapy, the California biotech is partnering with Merck to test T-Vec in combination with the PD-1 drug, Keytruda, in patients with head and neck cancer.

Celldex's brain cancer vaccine Rintega posts survival edge in PhII

Not only is Hampton, NJ-based Celldex Therapeutics operating in the challenging cancer vaccines field, but it's working on a treatment for one of the most difficult-to-treat cancers. But with positive new Phase II survival data in hand, the company could eventually have a winner.

Amgen publishes pivotal T-Vec data as it awaits FDA decision

Riding momentum from an FDA advisory committee recommendation last month, Amgen rolled out its data from a pivotal study of its cancer vaccine talimogene laherparepvec (T-Vec) on Tuesday as it awaits the agency's final decision, expected later this year.

Regeneus gets green light to move personalized cancer vaccine into PhI

Australian biotech Regeneus is set to become the latest company to brave moving a personalized cancer vaccine into the clinic. The company picked up clearance from an ethics committee this week, clearing the last remaining obstacle between it and the start of an early-phase study.

U.K.'s PsiOxus scores $39M for colorectal cancer vaccine combo trial

Oxford-based PsiOxus closed a Series C financing round, scoring £25 million ($39 million) to advance its lead candidate, enadenotucirev, an oncolytic virus aimed at fighting colorectal tumors. The funding came from GlaxoSmithKline's VC unit and U.K. heavyweight investor Neil Woodford's new $1.2 billion fund.

NewLink continues cancer vaccine Ph III trial with interim data under wraps

Without convincing data to prove a win for NewLink Genetics' late-stage cancer vaccine, it will go full steam ahead on its Phase III trial, the company announced Monday. The IMPRESS trial for algenpantucel-L--or HyperAcute pancreas--will continue with no changes following the second planned interim analysis for the trial.

Aduro swings for the fences with $119M IPO

Aduro Biotech is picking up in 2015 where it left off last year, riding momentum into an upsized $119 million IPO to fund its breakthrough pancreatic cancer immunotherapy combo CRS-207 and GVAX.